Prime Medicine showcases its first in vivo editing data in monkeys and mice
Prime Medicine, a biotech company developing a new class of gene editors that promises to make nearly any change to any gene, said the first tests of its technology in animals were successful, paving the way to human studies.
One of the company’s experimental treatments is for a rare liver condition called glycogen storage disease Ib (GSDIb). When delivered via lipid nanoparticle infusion, the in vivo therapy edited up to 50% of liver cells in monkeys and up to 56% of liver cells in mice — far more than the estimated 10% editing needed for a therapeutic effect.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
